DR REDDYS
More than family business: Drugmakers make costly, long-term strategic shifts as next generation steps into bigger roles
India's family-run pharmaceutical companies are entering a new phase as the next generation takes on larger leadership roles and steers businesses towards complex generics, peptides, biologics, contract manufacturing and advanced therapeutics. Laurus Labs, Granules India, Bharat Biotech, Sun Pharma and Torrent Pharma are investing in capabilities that require greater scientific expertise, significant capital and longer gestation periods. The key question is whether the successors can turn these long-term bets into sustainable growth and create lasting value for investors.
Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return
In 2026, India's pharmaceutical stocks are making headlines with impressive year-to-date gains. This surge is driven by strong domestic demand alongside enhanced profitability from new product launches. Notable players like Laurus Labs and Gland Pharma have recorded remarkable returns, topping 100%. Amid challenges faced by other sectors, the pharmaceutical field demonstrates resilience. Analysts are optimistic but advise exercising caution regarding potential market volatility and the durability of this sector's performance.
Dr Reddy's Laboratories receives ANVISA approval for generic semaglutide injection in Brazil
Dr Reddy’s Laboratories obtained marketing authorisation from Brazil’s ANVISA for a generic semaglutide injection. The product will be available as a pre-filled, multi-dose pen in two dosages for weekly administration. This drug targets treatment for type 2 diabetes alongside diet and exercise, particularly in patient groups needing alternative therapies. Brazil's diabetes prevalence creates significant market demand, estimated at approximately $244.6 million.
Lighthouse Learning in talks to acquire Hyderabad's Kennedy School
Lighthouse Learning Group, previously EuroKids International, is negotiating to acquire Kennedy High and Meru International School. These acquisitions, valued at Rs 400 crore each, are expected to finalize in the coming weeks. The company aims to expand its network of K-12 schools to 100 over the next few years. Lighthouse Learning has undertaken several acquisitions since 2021 to grow its education portfolio.
Astrobase, Bayer to invest Rs 700 crore in Karnataka, creating nearly 1,500 jobs
Astrobase and Bayer have announced a combined investment of Rs 700 crore in Karnataka. Astrobase will invest Rs 500 crore to set up a manufacturing facility for rocket engines. This project aims to create approximately 1,250 jobs in the region. Bayer plans to invest Rs 200 crore to establish a Global Capability Centre, generating around 220 jobs. Both investments reflect a growing interest in expanding industrial capabilities in Karnataka.
FPI holding hits multi-year lows in 70% of top 100 Indian companies
Foreign investors have significantly reduced their holdings in nearly 70% of India's leading companies in recent years. Major firms, including banks and IT sectors, are seeing foreign ownership decline to multi-decade lows. This decrease in foreign investments mirrors diminished expectations for growth in India relative to other global markets. Although some companies experience slight increases in foreign ownership, they still remain at historical lows.
- Go To Page 1
Amit Shah offers prayers at Bhagya Laxmi temple in Hyderabad ahead of BJP's 'Loktantra Bachao, Arajakta Hatao' padyatra
Amit Shah visited the Sri Bhagya Laxmi Mata temple in Hyderabad and offered prayers. He is participating in the BJP's nationwide campaign titled 'Loktantra Bachao, Arajakta Hatao'. The campaign is aimed at countering the opposition's narrative and allegations against the BJP. Shah's padyatra will start from the Swami Vivekananda statue and end at the Dr. B.R. Ambedkar statue. This rally intends to protest against the Congress administration in Telangana.
Times Internet Half Marathon, Hyderabad: Celebrating a successful race and the people behind it
The Times Internet Half Marathon in Hyderabad wrapped up on a high note, uniting a diverse group of runners across multiple distance categories. With robust support from various partners, the event celebrated fitness and camaraderie. Next on the agenda, the series promises exciting races in Bengaluru, Mumbai, and Delhi, keeping the spirit of running alive.
Short-term headwinds, yes; owning the ecosystem is better: 20 healthcare stocks with downside risk of 23% to upside potential of 41%
The healthcare sector is under scrutiny. The issue is pricing: What medicines cost and on what hospitals and the rest of the health ecosystem charge. And both the government and the courts have stepped in. At one level, that is not entirely a bad thing. Check out Stock Reports Plus, powered by Refinitiv, for price targets of over 4,000 listed stocks along with detailed company analysis focusing on five key components – earnings, fundamentals, relative valuation, risk, and price momentum – to generate standardised scores. SR+ Reports is a complimentary offering to ETPrime members.
Court discharges former drug regulator S Eswara Reddy, three others in corruption case
The court found that the call recordings relied on by the prosecution did not attribute criminality to Reddy. None of the accused, it noted, had said in the recordings that Reddy demanded a bribe on any particular day or time to favour Bengaluru-based Biocon Biologics Ltd (BBL).
India, Mexico begin talks for trade pact; aim to boost commerce, investments
India and Mexico have initiated negotiations for a preferential trade agreement to enhance bilateral trade and investment. The agreement aims to create new economic opportunities while addressing market access, customs procedures, and trade facilitation. Discussions included organising a Mexican business mission to India in early 2027 to improve commercial ties. India had a trade surplus with Mexico, largely due to exports in autos and pharmaceuticals.
AI halves drug discovery times, but =trial bottleneck remains a costly reality
Novo Nordisk, Sanofi and Dr Reddy’s Laboratories are among the companies exploring applications ranging from drug discovery to laboratory automation and research.
Two Trades for Today: A top pharma company for a 5.3% upmove, a mid-cap chemical maker’s stock for an almost 7% rise
Our technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical calls for today.
Mankind Pharma shares key business developments from Q2 & H1 of FY27
The company outperformed the market by 1.1 times in both chronic and acute therapies. Cardiac and anti-diabetes brands registered growth of 18.7% and 15.8%, respectively. In acute therapies, gastroenterology grew at 1.3 times the market rate, while vitamins, minerals and nutrients (VMN) expanded at 1.4 times that rate.
Market wrap: Dr Reddys, JSW Steel, Shriram Finance, Tata Consumer top gainers and losers on Nifty and Sensex on Monday
Indian equity markets snapped a four-day losing streak as Sensex and Nifty rebounded, supported by broad-based buying. Dr Reddy’s and JSW Steel led gainers, while rising India VIX signalled continued volatility and technical concerns about downside risks.
Stocks in news: Infosys, Kotak Mahindra Bank, YES Bank, Raymond, BPCL, Coforge and Senco Gold
Indian equity markets have faced a decline for four consecutive sessions, with the Nifty falling significantly. Various factors, including selling by foreign investors and rising crude oil prices, have contributed to this downturn. Notable stocks such as Infosys and Kotak Mahindra Bank have attracted investor attention due to their quarterly earnings. Upcoming developments may influence market sentiment further as investors remain watchful.
Dr Reddy's bets on generic semaglutide, biosimilars
Dr Reddy's domestic formulations business grew in the September quarter, while Revlimid sales declined in North America. A relaunch of generic semaglutide and the US launch of abatacept biosimilar are anticipated for future growth. The company aims to sell millions of pens for semaglutide with a focus on international markets. Furthermore, an expanding biosimilars portfolio aims to strengthen its position beyond traditional generics.
Great Eggspectations: Brown, free-range, omega-3 or protein-rich? What’s really worth paying for in an egg
India’s premium egg market is growing as health-conscious consumers pay more for free-range, cage-free and nutrient-enriched varieties. But higher prices do not always mean better nutrition. While farming practices and specialised feed can raise costs, experts say unclear labelling and limited verification make it difficult for consumers to assess what they are paying for.
Can dogs smell cancer in humans? Bengaluru founders says with AI, dogs can detect seven cancer symptoms with 90% accuracy
Startup Dognosis, based in Bengaluru, is creating an AI-driven, dog-assisted breath analysis to detect seven forms of cancer. Co-founded by Akash Kulgod and Itamar Bitan, the startup intends to introduce an at-home multicancer prescreening test in India by 2027.
DRL says cap on trade margins a positive, posts 36% dip in Q2 PAT
In the second quarter of FY2027, Dr. Reddy's Labs experienced a downturn in both revenue and profit. However, the company supports new trade margin regulations that aim to improve access to vital medicines. With a commitment to boosting its core business performance, management is also dedicated to exploring growth avenues.
Indian pharma: Unethical practices, marketing rules under lens; new review body set up
The review comes against the backdrop of the Uniform Code for Pharmaceutical Marketing Practices (UCPMP), which was introduced in 2015 as a voluntary, industry-led mechanism to promote ethical conduct in pharmaceutical marketing and regulate interactions between drug companies and healthcare professionals.
Dr Reddy’s Q2 Results: Net profit falls 36% YoY to Rs 913 crore, revenue declines marginally
Dr Reddy’s Laboratories reported a 36% year-on-year profit decline to Rs 913.4 crore in Q2 FY27, while revenue slipped 1.5%. North America weakness pressured performance, offset partly by growth in India and emerging markets, alongside biosimilar approvals and strategic partnerships.
Bajaj Finserv says Deepak Reddy appointed as CEO designate of Bajaj General Insurance
Bajaj General Insurance has appointed Deepak Reddy as CEO designate from January 1, 2027. He will take over as managing director and CEO on April 1, 2027, subject to approval from the Insurance Regulatory and Development Authority of India (IRDAI).
Dr Reddy's rolls out new generic Ozempic brands amid Obeda supply disruption
Dr Reddy’s Laboratories has expanded its generic semaglutide portfolio with Obeda Pro and Obeda Plus after supplies of its original Obeda injection were halted in July for technical evaluation. The new brands are manufactured by Hetero Labs, while distributors say the company may discontinue Obeda injectable supplies. Dr Reddy’s denies a replacement strategy.
Stocks in news: Swiggy, Infosys, HPCL, eMudhra, Adani Power, Shriram Finance, Tata Motors and NLC India
Indian equity markets faced continued downward pressure, marked by persistent selling and negative global indicators. The Nifty 50 index saw a decline, with analysts pointing out critical resistance and support points. Numerous companies disclosed their financial results, showcasing a mix of profits and setbacks for the September quarter. As various firms prepare to announce their quarterly earnings, market participants should remain vigilant over the coming days.
Dr Reddy's gets DCGI nod for Zytorvi in advanced esophageal cancer
Dr Reddy's Laboratories has received approval for Zytorvi, an immunotherapy targeting advanced esophageal squamous cell carcinoma. This new indication allows treatment for adult patients with a combination of toripalimab, cisplatin, and paclitaxel. Approximately 80 percent of esophageal cancer cases in India are attributed to esophageal squamous cell carcinoma. The approval derives from positive results in the Phase 3 JUPITER-06 trial.
Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select players
India's pharmaceutical companies are expected to have a mixed performance in the upcoming September quarter. Companies like Sun Pharmaceutical Industries and Aurobindo Pharma are likely to report good growth. In contrast, Dr Reddy's Laboratories and Lupin may face challenges due to increased competition and a high base. Pricing pressure and elevated raw material costs are also expected to impact overall performance.
Market wrap: ITC, Apollo Hospital, Dr Reddy's Labs, Bajaj Auto top gainers and losers on Nifty and Sensex on Monday
Indian equity markets ended lower on Monday as rising bond yields and continued FII outflows weighed on sentiment. The Nifty fell 0.70% to 22,363, while the Sensex lost 0.76% to 71,925. FMCG stocks led sectoral losses, while auto stocks gained. Dr Reddy’s and Bajaj Auto topped Nifty gainers.
FSSAI pulls up Dr Reddy's, Nestle Health Science over Celevida claims
The Food Safety and Standards Authority of India (FSSAI) said the product was advertised as providing high-protein support for preserving lean muscle during GLP-1/GIP therapies, commonly used in weight-loss treatment.
Load More
